NDP Condemns Federal Government's Response to Pharmacare Study

Post by : Mina Rahman

NDP interim leader Don Davies has labeled the federal government’s response to a national pharmacare report as “shockingly dismissive,” calling for openness regarding the program’s future.

Davies, who played a role in negotiating the Pharmacare Act last year, described the government’s position as politically dishonest. This legislation, enacted over a year ago in the NDP and Liberals’ supply-and-confidence agreement during former Prime Minister Justin Trudeau's tenure, mandated the establishment of an expert committee to propose a universal, single-payer pharmacare system.

The committee delivered its recommendations to Health Minister Marjorie Michel in October, with the findings revealed to the public last month. It proposed that Ottawa fund an essential medications list that covers more than 90% of prescriptions, managed by an independent body, enabling Canadians to access medications at no charge using their health cards.

The report also recommended circumventing lengthy bilateral discussions with provinces and territories, urging legislation to enshrine the right to essential medicines in law.

When asked about adopting the recommendations, Michel stated that the government is reviewing the report but did not guarantee any action. “Independent expert panels have their opinions, but they are not binding for the government,” she remarked, underlining her role involves negotiations with provinces and territories, dismissing the notion of unilateral action.

Davies criticized this tactic, suggesting it shows the government dismissed the report prior to evaluating it. He noted that committee members and stakeholders have struggled to arrange a meeting with the health minister since the report’s public release.

Committee chair Dr. Nav Persaud emphasized the increasing necessity for pharmacare, particularly in light of global trade pressures affecting jobs, insurance, and drug pricing. Committee member Amy Lamb presented the report as a “nation-building investment” grounded in Canadian values.

Davies further pressed the government to fulfill its obligations under the Pharmacare Act by completing the initial phase, which focuses on negotiating arrangements regarding contraceptives and select diabetes medications. Currently, only four agreements—those with B.C., Manitoba, P.E.I., and Yukon—have been established, leaving a fragmented system viewed as inequitable by health advocates.

“The government continues to position itself as being in favor of public access to medications, yet hesitates at crucial junctures for real progress,” Davies commented.

Despite earlier campaign commitments to safeguard programs like pharmacare, the first budget from Prime Minister Mark Carney offers no additional funding beyond the $1.5 billion set for 2024, most of which is already assigned to existing agreements. The committee estimates the annual cost of funding an essential medications list could range from $6-10 billion, but anticipates net costs around $3 billion due to savings from competitive purchasing and current coverage.